Skip to content

CYCLO THERAPEUTICS, INC.: 10-Q filed 2021-08-16

What CYCLO THERAPEUTICS, INC. reported in its quarterly report filed 2021-08-16 (fiscal Q2 2021): 25 published measures, 66 facts as tagged in accession 0001437749-21-020153.

This filing

Form
10-Q (quarterly report)
Filed
2021-08-16
Fiscal period
fiscal Q2 2021
Accession
0001437749-21-020153 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All CYCLO THERAPEUTICS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2021-06-3014,243,375USD
At 2020-12-3114,187,964USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2021-06-3011,126,178USD
At 2021-03-3114,321,567USD
At 2020-12-3110,452,482USD
At 2020-06-30-1,920,039USD
At 2020-03-31-1,698,010USD
At 2019-12-31935,982USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2021-06-3011,463,098USD
At 2020-12-3112,846,113USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2021-04-01 to 2021-06-30-3,597,398USD91
2021-01-01 to 2021-06-30-7,634,013USD181
2021-01-01 to 2021-03-31-4,036,615USD90
2020-04-01 to 2020-06-30-2,192,392USD91
2020-01-01 to 2020-06-30-4,826,384USD182
2020-01-01 to 2020-03-31-2,633,992USD91

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2021-01-01 to 2021-06-30-9,366,785USD181
2020-01-01 to 2020-06-30-3,870,456USD182

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2021-01-01 to 2021-06-3022,500USD181
2020-01-01 to 2020-06-3053,127USD182

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2021-01-01 to 2021-06-307,986,101USD181
2020-01-01 to 2020-06-302,128,887USD182

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2021-01-01 to 2021-06-30-2,331USD181
2020-01-01 to 2020-06-30-33,795USD182

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2021-06-30-41,695,849USD
At 2020-12-31-34,061,836USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2021-04-01 to 2021-06-300USD91
2021-01-01 to 2021-06-300USD181
2020-04-01 to 2020-06-300USD91
2020-01-01 to 2020-06-300USD182

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2021-06-3067,997USD
At 2020-12-3153,910USD

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2021-04-01 to 2021-06-30-3,600,452USD91
2021-01-01 to 2021-06-30-7,637,728USD181
2020-04-01 to 2020-06-30-2,201,903USD91
2020-01-01 to 2020-06-30-4,843,943USD182

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2021-06-3014,120,569USD
At 2020-12-3114,050,237USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2021-06-303,035,165USD
At 2020-12-313,672,553USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2021-06-30182,431USD
At 2020-12-3171,017USD

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2021-06-30268,930USD
At 2020-12-31237,909USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2021-04-01 to 2021-06-302,643,544USD91
2021-01-01 to 2021-06-305,901,659USD181
2020-04-01 to 2020-06-301,713,435USD91
2020-01-01 to 2020-06-303,773,041USD182

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2021-06-306,435,816shares
At 2020-12-314,770,761shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2021-06-3052,821,383USD
At 2020-12-3144,513,841USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2021-06-3026,453USD
At 2020-12-3134,011USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2021-04-01 to 2021-06-30-3,597,398USD91
2021-01-01 to 2021-06-30-7,634,013USD181
2020-04-01 to 2020-06-30-2,192,392USD91
2020-01-01 to 2020-06-30-4,826,384USD182

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2021-01-01 to 2021-06-308,413USD181
2020-01-01 to 2020-06-306,236USD182

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2021-01-01 to 2021-06-300USD181
2020-01-01 to 2020-06-300USD182

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2021-01-01 to 2021-06-30111,414USD181
2020-01-01 to 2020-06-3017,804USD182

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2021-01-01 to 2021-06-3031,021USD181
2020-01-01 to 2020-06-30-26,021USD182

Inspect the source

Entity
CYCLO THERAPEUTICS, INC. / CIK 0000922247
Captured
2026-09-21T17:17:43.874Z
SEC response SHA-256
00eb7fd40e8240f18174ace9c17e250765347f97ee2730b0222250298ac67de3

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000922247.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))